Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temocillin vs meropenem for cephalosporin-resistant Enterobacterales bacteraemia (ASTARTÉ)
2023-508440-21-00Phase 3Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of temocillin in Bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Composite treatment success. Started May 2024; status: completed.
02
Drugs
temocillin
03
Conditions
Bacteraemia due to third-generation cephalosporin-resistant Enterobacterales
Beyond the preview
Go deeper on 2023-508440-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508440-21-00.